Navigation Links
IPC The Hospitalist Company, Inc. to Present at Deutsche Bank's 34th Annual Health Care Conference
Date:5/5/2009

NORTH HOLLYWOOD, Calif., May 5 /PRNewswire-FirstCall/ -- IPC The Hospitalist Company, Inc. (Nasdaq: IPCM), a leading national physician group practice company, announced today that management is scheduled to present at Deutsche Bank's 34th Annual Health Care Conference, which will be held on May 18th and 19th in Boston, MA. 

            Speaker:          Jeff Taylor, President and COO
            Date:             Monday, May 18, 2009
            Time:             10:40 - 11:15 A.M. Eastern
            Place:            InterContinental Boston

A live Web cast of the presentation will also be available by visiting the investor relations section of the Company's Web site. A replay of the presentation will be available for 30 days.

About IPC The Hospitalist Company

IPC The Hospitalist Company, Inc. (Nasdaq: IPCM) is a leading national physician group practice company focused on the delivery of hospitalist medicine services. IPC's physicians and affiliated providers manage the care of hospitalized patients in coordination with primary care physicians and specialists. The Company provides its hospitalists with the comprehensive training, information technology, and management support systems necessary to improve the quality and reduce the cost of inpatient care in the facilities it serves. For more information, visit the IPC website at www.hospitalist.com.

    Contacts:
    Devra Shapiro                         Amy Glynn/Nick Laudico
    IPC The Hospitalist Company, Inc.     The Ruth Group
    (818) 766-3502                        646-536-7023/7030
                                          '/>"/>
SOURCE  IPC The Hospitalist Company, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 

Related medicine news :

1. IPC The Hospitalist Company Reports Record First Quarter 2009 Results
2. IPC The Hospitalist Company, Inc. to Report First Quarter 2009 Financial Results
3. IPC The Hospitalist Company Presents IPC Hospitalist of the Year Award to Tim Osonma, M.D.
4. IPC The Hospitalist Company Acquires Arizona Practice
5. Spokane Hospitals Engage Sound Inpatient Physicians(TM) as Hospitalists in Spokane
6. IPC The Hospitalist Company Adopts E-Proxy to Reduce Environmental Impact
7. IPC The Hospitalist Company Reports Record Fourth Quarter and Full Year 2008 Results
8. IPC The Hospitalist Company Receives Best IPO Award from Los Angeles Venture Association
9. IPC The Hospitalist Company Acquires Missouri Practice Group
10. IPC The Hospitalist Company, Inc. to Present at 27th Annual J.P. Morgan Healthcare Conference
11. Physician Staffing Trends and Hospitalist Jobs Fuel Growth at Locum Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21 (HealthDay News) -- Urban elementary school ... experience sleep problems and suffer academically, new research ... aged seven to nine, we found that compromised ... and impaired academic performance," said study author ... human behavior at Brown University,s Alpert Medical School ...
(Date:5/21/2013)... Minn. Positively charged gold nanoparticles are usually ... to avoid nanoparticle toxicity. Mayo Clinic researchers found ... nanoparticles effective against ovarian cancer cells. The discovery ... the Journal of Biological Chemistry ., "This ... cancer cells by preventing the cell death or ...
(Date:5/21/2013)... May 21, 2013 Representatives with Hammerhead Bicycles ... a success that the company has achieved its overall goal ... day one was to move Hammerhead Bicycles from a house ... President Scott Robertson. , Robertson explained that the bike shop ... to exclusively focus on all things 29er and 650b. ...
(Date:5/21/2013)... the sound of galloping hooves behind you, your immediate reaction ... it is actually a zebra approaching. Doctors are trained to ... their practices, and as they rarely or never meet a ... takes many years to reach the right diagnosis. A new ... many cases. , Ole Winther is Associate Professor at ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Two-thirds of ... non-small cell lung cancer reported that they engage in ... medicine use, according to new findings from the ... Kantar Health . The research will be presented ... (International Society for Pharmacoeconomics and Outcomes Research) in New ...
Breaking Medicine News(10 mins):Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2Health News:Hammerhead Bicycles Now a Standalone Brand 2Health News:New search engine finds rare diagnoses 2Health News:New search engine finds rare diagnoses 3Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3
... (ASX: PGL; Nasdaq: PGLA) announced today that its ... status by the U.S. Food,and Drug Administration (FDA). ... 88 for the prevention of tumor recurrence following ... primary liver,cancer). Under the FDA Modernization Act ...
... Urgent Health Problems Report Highest Satisfaction When Seen by ... , Patient satisfaction with after-hours care for an urgent ... physician or their physicians after-hours clinic, compared with a ... services. According to a survey of 1,227 patients from ...
... seldom questioned, study found , , MONDAY, Sept. 24 (HealthDay ... some of their neediest patients, a new study suggests ... that raise suicide risk. , U.S. researchers recruited ... showing signs of depression or a similar disorder. , ...
... for her contributions to kidney ... ... a nationwide patient advocacy group comprised of more than 20,000,dialysis and pre-dialysis ... Entitled, Celebrating the Empowerment of,Kidney Patients, the event brought together dialysis patients ...
... N.C., Sept. 24 SalesForce4Hire(R), a provider of,custom ... Science industries,today announced the opening of its new ... allows SalesForce4Hire to expand its custom sales focus ... size of its sales,support call center. This new ...
... Robust Clinical Data Package Provided in NDA Demonstrates ... Safety of Once-Daily Tramadol Formulation, LAVAL, QC, Sept. ... announced that is has requested a meeting with the ... Drug,Application (NDA) for its once-daily formulation of tramadol. Based ...
Cached Medicine News:Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 2Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 3Health News:September/October 2007 Annals of Family Medicine tip sheet 2Health News:September/October 2007 Annals of Family Medicine tip sheet 3Health News:September/October 2007 Annals of Family Medicine tip sheet 4Health News:September/October 2007 Annals of Family Medicine tip sheet 5Health News:September/October 2007 Annals of Family Medicine tip sheet 6Health News:September/October 2007 Annals of Family Medicine tip sheet 7Health News:Doctors Often Fail to Spot Suicidal Patients 2Health News:Doctors Often Fail to Spot Suicidal Patients 3Health News:Nation's Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care 2Health News:Nation's Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care 3Health News:SalesForce4Hire Opens New Office 2Health News:Labopharm provides update on U.S. regulatory process for once-daily Tramadol 2Health News:Labopharm provides update on U.S. regulatory process for once-daily Tramadol 3
(Date:5/21/2013)... Calif. , May 21, 2013 Abaxis, ... blood analysis systems, announced today that Martin ... at the Stifel Annual Dental & Veterinary Conference on ... conference will be held at Le Parker Meridien Hotel ... About Abaxis Abaxis develops, manufactures, markets ...
(Date:5/21/2013)... JUPITER, Fla. , May 21, 2013  BioRestorative ... a life sciences company focused on developing stem cell ... Mark Weinreb , its President and CEO, ... The conference will be held on Thursday, ... at 109 E 42nd Street in New York City.  ...
(Date:5/21/2013)... 2013 Ceregene, Inc. today announced additional ... double-blind, randomized, controlled Phase 2b clinical study of ... designed to deliver the neurotrophic factor neurturin, for ... robust response to CERE-120 in Parkinson,s patients diagnosed ... those diagnosed 10 years or more (p<.005), as ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
... Nov. 18, 2010 The Pharmacy Technician ... Melissa Murer Corrigan, will serve as the 2011 president ... be installed at the ICE Annual Education Conference on ... organization that provides educational, networking and advocacy resources for ...
... 2010 Cell Therapeutics, Inc. ("CTI") (Nasdaq and ... Application ("MAA") seeking approval for Pixuvri™ (pixantrone dimaleate) ... relapsed or refractory aggressive non-Hodgkin,s lymphoma ("NHL") was ... Medicines Agency ("EMA"). Validation indicates that the application ...
Cached Medicine Technology:Melissa Murer Corrigan to Serve as 2011 ICE President 2The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 2The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 3
... a Q-switched ruby laser system ... nm. High Performance Combined with ... combination of high performance and ... mode effectively destroys the (natural ...
A Powerful New Quantitative Immunoassay for Monitoring Bladder Cancer Patients. Useful in Monitoring Patients for,Disease Progression and Recurrence....
... Test is an in vitro immunoassay intended for ... tumor associated antigen. It is indicated for use ... cancer in conjunction with cystoscopy or when prescribed ... by the FDA for prescription home use in ...
... is a quantitative microplate enzyme immunoassay that detects ... have very small amounts of NMP22 protein in ... is often elevated in the urine of patients ... the disease. The use of the NMP22 protein ...
Medicine Products: